-+ 0.00%
-+ 0.00%
-+ 0.00%

CITIUS ONCOLOGY INC - PHASE 1 STUDY SHOWS 24% OBJECTIVE RESPONSE RATE, 48% CLINICAL BENEFIT RATE

Reuters·03/10/2026 12:47:00

Please log in to view news